Forsta AP Fonden Lowers Stock Position in Insulet Co. (NASDAQ:PODD)

Forsta AP Fonden cut its position in Insulet Co. (NASDAQ:PODD - Free Report) by 3.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,500 shares of the medical instruments supplier's stock after selling 1,200 shares during the quarter. Forsta AP Fonden owned about 0.05% of Insulet worth $9,790,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in PODD. Integrated Wealth Concepts LLC raised its holdings in Insulet by 1.7% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier's stock valued at $596,000 after acquiring an additional 42 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of Insulet by 1.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier's stock valued at $1,146,000 after purchasing an additional 43 shares during the period. Glenmede Trust Co. NA raised its stake in shares of Insulet by 2.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier's stock valued at $484,000 after purchasing an additional 47 shares during the period. Graypoint LLC lifted its holdings in Insulet by 5.3% during the 4th quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier's stock worth $243,000 after purchasing an additional 47 shares in the last quarter. Finally, Wedmont Private Capital boosted its stake in Insulet by 3.5% in the 3rd quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier's stock worth $326,000 after purchasing an additional 48 shares during the period.

Insulet Stock Up 0.6 %

PODD traded up $1.56 during trading on Monday, hitting $279.94. 224,981 shares of the company's stock traded hands, compared to its average volume of 538,651. The stock has a market capitalization of $19.63 billion, a price-to-earnings ratio of 47.99, a PEG ratio of 3.49 and a beta of 1.23. The company's 50 day simple moving average is $268.69 and its two-hundred day simple moving average is $238.50. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $286.39. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 EPS for the quarter, beating the consensus estimate of $0.77 by $0.13. Insulet had a return on equity of 27.98% and a net margin of 21.22%. The company had revenue of $543.90 million for the quarter, compared to analysts' expectations of $518.50 million. During the same period last year, the firm posted $0.71 earnings per share. Analysts predict that Insulet Co. will post 3.22 earnings per share for the current fiscal year.

Insider Activity

In other Insulet news, CAO Lauren Budden sold 915 shares of the business's stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at $1,580,129.46. The trade was a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by corporate insiders.

Analyst Ratings Changes

PODD has been the topic of a number of recent analyst reports. Morgan Stanley increased their price target on shares of Insulet from $234.00 to $317.00 and gave the stock an "overweight" rating in a report on Monday, November 11th. Raymond James upped their price target on shares of Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a report on Monday, October 14th. Canaccord Genuity Group lifted their price objective on Insulet from $269.00 to $304.00 and gave the company a "buy" rating in a research note on Monday, December 9th. Sanford C. Bernstein assumed coverage on Insulet in a report on Wednesday, November 6th. They issued an "outperform" rating and a $300.00 price target on the stock. Finally, Wells Fargo & Company boosted their price objective on Insulet from $290.00 to $305.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $272.81.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.